Skip to main content
. 2023 May 11;22:415–432. doi: 10.17179/excli2023-6122

Table 4. Phase 3 trials of ICIs or their combinations in NSCLC (Zerdes et al., 2018; Pinto et al., 2019; Paz-Ares et al., 2022, changed).

Table 4